Physician profile
Daniel B Shepler
NPI 1184087629
$4,115.33
in general payments reported to CMS, 2019-2025
31 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $167 · 2023: $986 · 2024: $1,449 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.97 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.41 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $445.94 | 2024-2025 | Hetlioz, Fanapt |
| Corium, LLC | $348.14 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $346.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $342.55 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.46 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $243.31 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $216.68 | 2022-2024 | Lybalvi, Aristada |
| Noven Therapeutics, LLC | $159.32 | 2023-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $135.61 | 2021-2024 | Trintellix |
| Bausch Health US, LLC | $119.21 | 2023-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $82.72 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $77.64 | 2023-2024 | Jornay Pm |
| Neos Therapeutics, LP | $49.99 | 2023-2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $40.66 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $35.96 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $33.47 | 2023-2024 | Quviviq |
| Jazz Pharmaceuticals INC. | $29.91 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $26.98 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $26.89 | 2024 | Qelbree |
| Biogen, INC. | $22.49 | 2025 | Zurzuvae |
| Janssen Pharmaceuticals, INC | $21.43 | 2025 | Spravato |
| Lilly USA, LLC | $19.12 | 2022 | |
| Novo Nordisk INC | $18.42 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $18.34 | 2024 | Lumryz |
| Cranial Technologies, INC | $18.29 | 2023 | Doc Band |
| Almatica Pharma LLC | $17.65 | 2024 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $15.81 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.63 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $15.13 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shepler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.